AbCellera Biologics (ABCL)
AbCellera Biologics on one page: short interest, daily short volume, fails to deliver, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
30.9M
Short interest
settlement 2026-10-15
5.6
Days to cover
-0.4 days vs prior
40.7%
Short share of volume
2026-11-02
1,463
Fails to deliver
settlement 2026-10-06
Thu 5 Nov
Next earnings
estimated date
$1.5M
Insider flow, 90 days
4 buys, 0 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in ABCL is 30,934,912 shares, down 2,995,375 shares over the last month. Over the last 48 readings it ranged from 15,887,450 shares (13 December 2024) to 55,161,166 shares (31 October 2025). At the reported average volume of 5.5M shares a day that is 5.6 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/abcl" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 30,934,912 | -4.8% | 5,491,586 | 5.63 |
| 2026-09-30 | 32,498,416 | -4.2% | 5,432,498 | 5.98 |
| 2026-09-15 | 33,930,287 | -2.4% | 3,524,143 | 9.63 |
| 2026-08-31 | 34,752,708 | -15.9% | 6,714,875 | 5.18 |
| 2026-08-14 | 41,340,862 | -14.4% | 13,580,333 | 3.04 |
| 2026-07-31 | 48,318,516 | +7.1% | 5,001,668 | 9.66 |
| 2026-07-15 | 45,110,268 | -7.1% | 6,470,475 | 6.97 |
| 2026-06-30 | 48,564,126 | +8.1% | 9,106,011 | 5.33 |
| 2026-06-15 | 44,909,557 | -4.7% | 6,292,428 | 7.14 |
| 2026-05-29 | 47,119,903 | +9.7% | 8,447,671 | 5.58 |
| 2026-05-15 | 42,950,817 | -3.4% | 10,132,809 | 4.24 |
| 2026-04-30 | 44,457,643 | -6.8% | 7,436,554 | 5.98 |
| 2026-04-15 | 47,699,890 | -5.4% | 2,809,954 | 16.98 |
| 2026-03-31 | 50,425,478 | +0.1% | 2,220,409 | 22.71 |
| 2026-03-13 | 50,399,213 | -1.8% | 3,193,906 | 15.78 |
| 2026-02-27 | 51,320,387 | +2.2% | 3,613,919 | 14.20 |
| 2026-02-13 | 50,215,439 | +2.7% | 4,882,637 | 10.28 |
| 2026-01-30 | 48,902,371 | +4.0% | 4,303,024 | 11.36 |
| 2026-01-15 | 47,000,042 | -2.6% | 5,298,496 | 8.87 |
| 2025-12-31 | 48,266,214 | -4.4% | 3,414,694 | 14.13 |
| 2025-12-15 | 50,505,133 | -0.7% | 2,944,659 | 17.15 |
| 2025-11-28 | 50,842,609 | -6.6% | 4,576,412 | 11.11 |
| 2025-11-14 | 54,443,811 | -1.3% | 5,900,042 | 9.23 |
| 2025-10-31 | 55,161,166 | +3.7% | 4,009,878 | 13.76 |
| 2025-10-15 | 53,201,052 | +15.3% | 7,548,944 | 7.05 |
| 2025-09-30 | 46,141,939 | +4.0% | 5,189,427 | 8.89 |
| 2025-09-15 | 44,375,292 | +2.6% | 3,933,938 | 11.28 |
| 2025-08-29 | 43,232,762 | +3.5% | 3,694,394 | 11.70 |
| 2025-08-15 | 41,784,407 | +5.0% | 6,213,543 | 6.72 |
| 2025-07-31 | 39,805,894 | +11.4% | 7,014,840 | 5.67 |
| 2025-07-15 | 35,716,688 | +17.4% | 6,202,757 | 5.76 |
| 2025-06-30 | 30,416,351 | +14.7% | 7,464,192 | 4.07 |
| 2025-06-13 | 26,518,430 | +16.1% | 7,921,460 | 3.35 |
| 2025-05-30 | 22,838,994 | +1.4% | 2,439,966 | 9.36 |
| 2025-05-15 | 22,514,981 | -2.1% | 5,461,341 | 4.12 |
| 2025-04-30 | 23,010,233 | -3.2% | 3,655,913 | 6.29 |
| 2025-04-15 | 23,779,702 | +0.7% | 4,705,236 | 5.05 |
| 2025-03-31 | 23,624,883 | +3.7% | 3,312,608 | 7.13 |
| 2025-03-14 | 22,787,356 | +14.5% | 4,390,421 | 5.19 |
| 2025-02-28 | 19,899,185 | -1.0% | 5,390,444 | 3.69 |
| 2025-02-14 | 20,096,109 | +9.0% | 3,640,896 | 5.52 |
| 2025-01-31 | 18,429,713 | +6.8% | 3,947,342 | 4.67 |
| 2025-01-15 | 17,258,203 | +4.1% | 3,820,559 | 4.52 |
| 2024-12-31 | 16,573,213 | +4.3% | 2,596,772 | 6.38 |
| 2024-12-13 | 15,887,450 | -2.2% | 2,512,894 | 6.32 |
| 2024-11-29 | 16,252,124 | +2.0% | 2,208,517 | 7.36 |
| 2024-11-15 | 15,933,087 | -4.3% | 3,155,991 | 5.05 |
| 2024-10-31 | 16,641,378 | -4.1% | 1,880,754 | 8.85 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of ABCL volume is 40.7%, down 14.0 points over the last five sessions. Over the last 30 readings it ranged from 32.8% (30 October 2026) to 61.4% (23 October 2026). The latest reading is 4.5 points below the 30-session average of 45.2%, on 1.3M shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 519K | 1.3M | 40.7% | 19,984 |
| 2026-10-30 | 549K | 1.7M | 32.8% | 8,534 |
| 2026-10-29 | 474K | 1.1M | 41.3% | 16,613 |
| 2026-10-28 | 686K | 1.4M | 50.0% | 4,476 |
| 2026-10-27 | 680K | 1.8M | 38.0% | 6,819 |
| 2026-10-26 | 731K | 1.3M | 54.7% | 310 |
| 2026-10-23 | 838K | 1.4M | 61.4% | 2,107 |
| 2026-10-22 | 652K | 1.5M | 44.4% | 2,400 |
| 2026-10-21 | 762K | 1.4M | 54.4% | 0 |
| 2026-10-20 | 1.2M | 2.1M | 55.8% | 1,368 |
| 2026-10-19 | 538K | 1.5M | 35.9% | 9,711 |
| 2026-10-16 | 836K | 1.9M | 44.9% | 36,093 |
| 2026-10-15 | 815K | 2.1M | 39.7% | 1,668 |
| 2026-10-14 | 459K | 1.3M | 36.0% | 4,842 |
| 2026-10-13 | 418K | 1.2M | 34.0% | 100 |
| 2026-10-12 | 916K | 2.2M | 42.1% | 47,620 |
| 2026-10-09 | 775K | 2.3M | 33.5% | 1,739 |
| 2026-10-08 | 1.7M | 3.5M | 49.9% | 1,147 |
| 2026-10-07 | 1.1M | 2.4M | 46.0% | 2,000 |
| 2026-10-06 | 2.0M | 4.3M | 47.1% | 5,261 |
| 2026-10-05 | 720K | 1.7M | 41.9% | 6,937 |
| 2026-10-02 | 851K | 1.7M | 51.5% | 13,676 |
| 2026-10-01 | 2.0M | 3.6M | 56.5% | 13,603 |
| 2026-09-30 | 1.2M | 2.2M | 54.6% | 4,300 |
| 2026-09-29 | 2.2M | 4.3M | 50.7% | 4,316 |
| 2026-09-28 | 1.9M | 3.4M | 55.3% | 4,115 |
| 2026-09-25 | 638K | 1.3M | 48.8% | 0 |
| 2026-09-24 | 654K | 1.9M | 34.0% | 6,433 |
| 2026-09-23 | 743K | 2.0M | 37.7% | 5,811 |
| 2026-09-22 | 907K | 2.1M | 42.5% | 2,327 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 6 October 2026, the fails-to-deliver balance in ABCL is 1,463 shares, up 1,060 shares over the last settlement date. Over the last 30 readings it ranged from 343 shares (2 September 2026) to 1,390,030 shares (11 August 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-06 | 1,463 | $13.78 | $20K |
| 2026-10-05 | 403 | $13.74 | $6K |
| 2026-10-02 | 20,506 | $13.91 | $285K |
| 2026-09-29 | 9,515 | $13.92 | $132K |
| 2026-09-22 | 4,766 | $12.66 | $60K |
| 2026-09-21 | 22,300 | $12.63 | $282K |
| 2026-09-18 | 6,300 | $12.73 | $80K |
| 2026-09-17 | 57,773 | $11.67 | $674K |
| 2026-09-16 | 4,803 | $11.41 | $55K |
| 2026-09-15 | 2,029 | $11.17 | $23K |
| 2026-09-09 | 1,537 | $11.44 | $18K |
| 2026-09-02 | 343 | $11.28 | $4K |
| 2026-08-28 | 3,200 | $12.40 | $40K |
| 2026-08-26 | 82,773 | $12.50 | $1.0M |
| 2026-08-25 | 20,898 | $10.61 | $222K |
| 2026-08-24 | 4,906 | $11.32 | $56K |
| 2026-08-21 | 17,277 | $11.57 | $200K |
| 2026-08-20 | 25,128 | $12.01 | $302K |
| 2026-08-18 | 314,619 | $11.20 | $3.5M |
| 2026-08-17 | 318,721 | $11.38 | $3.6M |
| 2026-08-14 | 320,864 | $10.97 | $3.5M |
| 2026-08-13 | 10,899 | $10.36 | $113K |
| 2026-08-12 | 279,162 | $9.76 | $2.7M |
| 2026-08-11 | 1,390,030 | $9.34 | $13.0M |
| 2026-08-10 | 170,430 | $6.93 | $1.2M |
| 2026-08-07 | 11,596 | $6.53 | $76K |
| 2026-08-06 | 39,560 | $5.92 | $234K |
| 2026-08-05 | 290,016 | $6.09 | $1.8M |
| 2026-08-04 | 28,498 | $5.83 | $166K |
| 2026-08-03 | 34,017 | $5.71 | $194K |
Insider trades
SEC Form 4, newest first. JSONInsiders at ABCL reported 4 open-market buys worth $1.5M in the last 90 days and no open-market sells. Latest filing: Hayden Michael R (Director) on 2026-08-24.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-08-24 | Hayden Michael R | Director | Buy | 54K | $10.64 | $570K | 1.4M |
| 2026-08-18 | Montalbano John S. | Director | Buy | 10K | $11.03 | $110K | 251K |
| 2026-08-14 | Booth Andrew | Chief Financial Officer | Buy | 37K | $10.32 | $384K | 483K |
| 2026-08-12 | Hayden Michael R | Director | Buy | 46K | $10.37 | $481K | 1.3M |
| 2026-08-11 | Hayden Michael R | Director | Gift | 50K | $0.00 | $0 | 1.3M |
| 2026-06-03 | Booth Andrew | Chief Financial Officer | Exercise or conversion | 250K | $0.19 | $48K | 446K |
| 2026-05-14 | Montalbano John S. | Director | Buy | 20K | $4.77 | $95K | 241K |
| 2026-02-27 | Booth Andrew | Chief Financial Officer | Buy | 43K | $3.42 | $146K | 196K |
| 2026-02-27 | Thermopylae Holdings Ltd. | 10% owner | Buy | 38K | $3.44 | $131K | 56.1M |
| 2026-02-26 | Thermopylae Holdings Ltd. | 10% owner | Buy | 177K | $3.27 | $580K | 56.1M |
| 2025-12-18 | Thermopylae Holdings Ltd. | 10% owner | Gift | 225K | $0.00 | $0 | 55.9M |
| 2025-11-26 | Montalbano John S. | Director | Buy | 50K | $3.57 | $178K | 221K |
| 2025-03-11 | Thermopylae Holdings Ltd. | TenPercentOwner | Buy | 344K | $2.16 | $742K | 56.1M |
| 2025-03-10 | Montalbano John S. | Director | Buy | 25K | $2.30 | $58K | 171K |
| 2025-03-06 | Montalbano John S. | Director | Buy | 60K | $2.34 | $140K | 146K |
| 2024-12-04 | Thermopylae Holdings Ltd. | TenPercentOwner | Gift | 286K | $0.00 | $0 | 55.8M |
| 2024-11-25 | Hansen Carl L. G. | Chief Executive Officer | Exercise or conversion | 56K | $2.70 | $152K | 898K |
| 2024-09-20 | Hansen Carl L. G. | Chief Executive Officer | Exercise or conversion | 56K | $2.70 | $152K | 842K |
| 2024-08-29 | Thermopylae Holdings Ltd. | TenPercentOwner | Buy | 284K | $2.61 | $740K | 56.1M |
| 2024-06-21 | Lecault Veronique | Chief Operating Officer | Exercise or conversion | 83K | $0.19 | $16K | 2.1M |
| 2024-05-31 | Hansen Carl L. G. | Chief Executive Officer | Exercise or conversion | 56K | $2.70 | $152K | 786K |
| 2024-02-26 | Hansen Carl L. G. | Chief Executive Officer | Exercise or conversion | 56K | $2.70 | $152K | 730K |
| 2023-12-19 | Thermopylae Holdings Ltd. | TenPercentOwner | Gift | 210K | $0.00 | $0 | 55.8M |
| 2023-11-23 | Hansen Carl L. G. | Chief Executive Officer | Exercise or conversion | 56K | $2.70 | $152K | 674K |
| 2023-11-08 | Montalbano John S. | Director | Buy | 10K | $4.46 | $45K | 86K |
| 2023-11-06 | Montalbano John S. | Director | Buy | 20K | $4.64 | $93K | 76K |
| 2023-09-22 | Hayden Michael R | Director | Buy | 20K | $4.91 | $98K | 1.3M |
| 2023-09-12 | Lecault Veronique | Chief Operating Officer | Buy | 20K | $5.19 | $104K | 2.0M |
| 2023-08-24 | Hansen Carl L. G. | Chief Executive Officer | Exercise or conversion | 56K | $2.70 | $152K | 617K |
| 2023-08-08 | Hayden Michael R | Director | Buy | 30K | $5.90 | $177K | 1.3M |
| 2023-05-26 | Thermopylae Holdings Ltd. | TenPercentOwner | Buy | 153K | $6.52 | $998K | 56.0M |
| 2023-05-26 | Booth Andrew | Chief Financial Officer | Buy | 15K | $6.85 | $99K | 153K |
| 2023-05-26 | Hansen Carl L. G. | Chief Executive Officer | Exercise or conversion | 56K | $2.70 | $152K | 561K |
| 2023-05-05 | Lecault Veronique | Chief Operating Officer | Exercise or conversion | 250K | $0.19 | $48K | 2.0M |
| 2023-02-22 | Hansen Carl L. G. | Chief Executive Officer | Exercise or conversion | 56K | $2.70 | $152K | 505K |
| 2022-12-20 | Booth Andrew | Chief Financial Officer | Exercise or conversion | 50K | $0.19 | $10K | 189K |
| 2022-12-20 | Booth Andrew | Chief Financial Officer | Gift | 50K | $0.00 | $0 | 139K |
| 2022-12-16 | Thermopylae Holdings Ltd. | TenPercentOwner | Buy | 85K | $10.10 | $860K | 55.9M |
| 2022-11-18 | Hansen Carl L. G. | Chief Executive Officer | Exercise or conversion | 56K | $2.70 | $152K | 449K |
| 2022-10-31 | Thermopylae Holdings Ltd. | TenPercentOwner | Gift | 70K | $0.00 | $0 | 55.8M |
| 2022-08-19 | Thermopylae Holdings Ltd. | TenPercentOwner | Buy | 200K | $11.46 | $2.3M | 55.8M |
| 2022-08-18 | Hansen Carl L. G. | Chief Executive Officer | Exercise or conversion | 56K | $2.70 | $152K | 393K |
| 2022-06-14 | Thermopylae Holdings Ltd. | TenPercentOwner | Buy | 9K | $8.05 | $74K | 55.6M |
| 2022-06-13 | Thermopylae Holdings Ltd. | TenPercentOwner | Buy | 55K | $8.03 | $441K | 55.6M |
| 2022-06-06 | Thermopylae Holdings Ltd. | TenPercentOwner | Buy | 65K | $7.50 | $484K | 55.6M |
| 2022-05-18 | Hansen Carl L. G. | Chief Executive Officer | Exercise or conversion | 56K | $2.70 | $152K | 337K |
| 2022-05-16 | Lecault Veronique | Chief Operating Officer | Buy | 200K | $6.34 | $1.3M | 1.8M |
| 2022-05-13 | Thermopylae Holdings Ltd. | TenPercentOwner | Buy | 300K | $7.26 | $2.2M | 55.5M |
| 2022-05-12 | Booth Andrew | Chief Financial Officer | Buy | 85K | $5.79 | $492K | 139K |
| 2022-05-12 | Thermopylae Holdings Ltd. | TenPercentOwner | Buy | 1.4M | $6.41 | $9.0M | 55.2M |
| 2022-03-04 | Montalbano John S. | Director | Buy | 10K | $8.54 | $85K | 56K |
| 2022-03-01 | Montalbano John S. | Director | Buy | 20K | $9.05 | $181K | 46K |
| 2022-02-28 | Lecault Veronique | Chief Operating Officer | Buy | 231K | $8.66 | $2.0M | 1.6M |
| 2022-02-22 | Hansen Carl L. G. | Chief Executive Officer | Exercise or conversion | 56K | $2.70 | $152K | 281K |
| 2021-12-10 | Booth Andrew | Chief Financial Officer | Exercise or conversion | 500K | $0.32 | $160K | 554K |
| 2021-12-08 | Lecault Veronique | Chief Operating Officer | Exercise or conversion | 250K | $0.19 | $48K | 1.6M |
| 2021-12-03 | Lo Andrew | Director | Buy | 87K | $14.02 | $1.2M | 87K |
| 2021-11-30 | Lecault Veronique | Chief Operating Officer | Exercise or conversion | 83K | $14.96 | $1.2M | 1.4M |
| 2021-11-30 | Lecault Veronique | Chief Operating Officer | Exercise or conversion | 83K | $0.19 | $16K | 1.4M |
| 2021-11-18 | Hansen Carl L. G. | Chief Executive Officer | Exercise or conversion | 225K | $15.03 | $3.4M | 225K |
| 2021-11-11 | Thermopylae Holdings Ltd. | TenPercentOwner | Buy | 203K | $14.76 | $3.0M | 55.8M |
| 2021-11-11 | Booth Andrew | Chief Financial Officer | Buy | 54K | $14.74 | $789K | 54K |
| 2021-11-11 | Booth Andrew | Chief Financial Officer | Buy | 14K | $14.61 | $205K | 131K |
| 2021-09-13 | Hayden Michael R | Director | Exercise or conversion | 270K | $17.73 | $4.8M | 1.3M |
| 2021-09-01 | HAMER JOHN | Director | Sell | 137K | $16.93 | $2.3M | 129K |
| 2021-09-01 | Falconer Ester | Chief Technology Officer | Exercise or conversion | 875K | $16.89 | $14.8M | 875K |
| 2021-08-31 | HAMER JOHN | Director | Sell | 163K | $16.95 | $2.8M | 266K |
| 2021-08-16 | Montalbano John S. | Director | Buy | 6K | $17.23 | $103K | 26K |
| 2021-06-22 | Hayden Michael R | Director | Sell | 100K | $25.50 | $2.5M | 1.0M |
| 2021-06-18 | Ocko Matthew | TenPercentOwner | Other transaction | 74K | $0.00 | $0 | 74K |
| 2021-06-18 | Ocko Matthew | TenPercentOwner | Other transaction | 5.0M | $0.00 | $0 | 24.1M |
| 2021-06-18 | HAMER JOHN | Director,TenPercentOwner | Other transaction | 5.0M | $0.00 | $0 | 24.1M |
| 2021-06-18 | HAMER JOHN | Director,TenPercentOwner | Other transaction | 74K | $0.00 | $0 | 74K |
| 2021-06-15 | Lecault Veronique | Chief Operating Officer | Exercise or conversion | 333K | $0.19 | $63K | 1.3M |
| 2021-06-09 | Falconer Ester | Chief Technology Officer | Sell | 1.0M | $25.50 | $25.5M | 0 |
| 2021-06-09 | Booth Andrew | Chief Financial Officer | Sell | 1.2M | $25.50 | $30.6M | 0 |
| 2021-06-09 | Stimart Tryn | Chief Legal Officer | Sell | 1.0M | $25.50 | $25.5M | 250 |
| 2021-06-09 | Lecault Veronique | Chief Operating Officer | Sell | 1.0M | $25.50 | $25.5M | 274K |
| 2021-06-09 | Hansen Carl L. G. | Chief Executive Officer | Sell | 5.6M | $24.03 | $134.5M | 55.6M |
| 2021-06-09 | Hansen Carl L. G. | Chief Executive Officer | Sell | 402K | $25.50 | $10.2M | 234K |
| 2021-06-09 | Thermopylae Holdings Ltd. | TenPercentOwner | Sell | 5.6M | $24.03 | $134.5M | 55.6M |
| 2021-06-07 | Booth Andrew | Chief Financial Officer | Exercise or conversion | 600K | $0.32 | $192K | 1.2M |
| 2021-06-07 | Booth Andrew | Chief Financial Officer | Exercise or conversion | 600K | $0.19 | $114K | 600K |
| 2021-06-07 | Stimart Tryn | Chief Legal Officer | Exercise or conversion | 750K | $0.32 | $240K | 750K |
| 2021-06-07 | Stimart Tryn | Chief Legal Officer | Exercise or conversion | 250K | $2.30 | $575K | 1.0M |
| 2021-03-19 | Falconer Ester | Chief Technology Officer | Exercise or conversion | 1.0M | $0.03 | $30K | 1.0M |
| 2020-12-15 | Stimart Tryn | Chief Legal Officer | Buy | 250 | $20.00 | $5K | 250 |
| 2020-12-15 | Stimart Tryn | Chief Legal Officer | Buy | 250 | $20.00 | $5K | 250 |
| 2020-12-15 | Hayden Michael R | Director | Buy | 74K | $20.00 | $1.5M | 118K |
| 2020-12-15 | Hayden Michael R | Director | Conversion | 118K | price not stated in the filing | not stated | 1.1M |
| 2020-12-15 | Lecault Veronique | Chief Operating Officer | Buy | 17K | $20.00 | $340K | 62K |
| 2020-12-15 | Lecault Veronique | Chief Operating Officer | Buy | 6K | $20.00 | $120K | 1.0M |
| 2020-12-15 | Unknown | Director | Buy | 20K | $20.00 | $400K | 20K |
| 2020-12-15 | Unknown | Director | Buy | 5K | $20.00 | $100K | 5K |
| 2020-12-15 | HAMER JOHN | Director,TenPercentOwner | Conversion | 29.1M | price not stated in the filing | not stated | 29.1M |
| 2020-12-15 | HAMER JOHN | Director,TenPercentOwner | Conversion | 29K | price not stated in the filing | not stated | 29.1M |
| 2020-12-15 | THIEL PETER | Director | Conversion | 3.8M | price not stated in the filing | not stated | 4.7M |
| 2020-12-15 | THIEL PETER | Director | Conversion | 25K | price not stated in the filing | not stated | 25K |
| 2020-12-15 | THIEL PETER | Director | Conversion | 2.5M | price not stated in the filing | not stated | 7.2M |
| 2020-12-15 | THIEL PETER | Director | Buy | 3.0M | $20.00 | $60.0M | 10.2M |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON4 holders report 5% or more of ABCL in their latest filing, all on Schedule 13G (passive). The largest reported stake is Felix J. Baker at 10.8% of the class (33,012,138 shares), filed 2026-05-07 for an event on 2026-04-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-05-07 | 13G/Ano. 2 | Felix J. Bakerparent holding company, individual | 33.0M | 10.8% | 2026-04-30 |
| 2026-05-07 | 13G/Ano. 2 | Julian C. Bakerparent holding company, individual | 33.0M | 10.8% | 2026-04-30 |
| 2026-05-07 | 13G/Ano. 2 | Baker Bros. Advisors (GP) LLCparent holding company, other entity | 33.0M | 10.8% | 2026-04-30 |
| 2026-05-07 | 13G/Ano. 2 | Baker Bros. Advisors LPinvestment adviser, partnership | 33.0M | 10.8% | 2026-04-30 |
13F holders
Tracked managers holding ABCL at their latest 13F. JSON5 of the 30 tracked managers held ABCL at their latest 13F, $106.6M in total at quarter-end prices. Two Sigma Investments is the largest at $81.9M (0.1% of its portfolio) as of 2026-06-30. Over the prior quarter 2 added shares and 3 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Two Sigma Investments | 2026-06-30 | 10.4M | $81.9M | 0.06% | -125K |
| Citadel Advisors | 2026-06-30 | 1.6M | $12.5M | 0.00% | +225K |
| Renaissance Technologies | 2026-06-30 | 991K | $7.8M | 0.01% | -520K |
| Millennium Management | 2026-06-30 | 519K | $4.1M | 0.00% | -776K |
| D. E. Shaw & Co. | 2026-06-30 | 45K | $357K | 0.00% | new |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) AbCellera Biologics reported revenue of $4.0M, down 76.3% from the same quarter a year earlier, and net loss of $55.4M (-0.18 diluted EPS). In FY 2025 it generated -$131.3M of operating cash flow.
- Cash
- $120.1M
- Equity
- $896.0M
- Total assets
- $1.31B
- Shares outstanding
- 306,611,466
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $4.0M | -$55.4M | -1368.6% | -0.18 |
| Q1 FY 2026 | 2026-03-31 | $8.3M | -$43.2M | -519.1% | -0.14 |
| Q4 FY 2025derived | 2025-12-31 | $44.9M | -$8.9M | -19.9% | n/a |
| Q3 FY 2025 | 2025-09-30 | $9.0M | -$57.1M | -637.8% | -0.19 |
| Q2 FY 2025 | 2025-06-30 | $17.1M | -$34.7M | -203.3% | -0.12 |
| Q1 FY 2025 | 2025-03-31 | $4.2M | -$45.6M | -1077.2% | -0.15 |
| Q4 FY 2024derived | 2024-12-31 | $5.0M | -$34.2M | -677.6% | n/a |
| Q3 FY 2024 | 2024-09-30 | $6.5M | -$51.1M | -785.4% | -0.17 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $75.1M | -$146.4M | -$131.3M | $42.8M | n/a | n/a |
| FY 2024 | 2024-12-31 | $28.8M | -$162.9M | -$108.6M | $78.4M | n/a | n/a |
| FY 2023 | 2023-12-31 | $38.0M | -$146.4M | -$43.9M | $76.9M | n/a | n/a |
| FY 2022 | 2022-12-31 | $485.4M | $158.5M | $277.4M | $70.7M | n/a | n/a |
| FY 2021 | 2021-12-31 | $375.2M | $153.5M | $244.6M | $58.5M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-08-03 from the cover page.
What this page is
AbCellera Biologics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows AbCellera Biologics (ABCL), SEC CIK 1703057, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-06.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-05-07.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-05.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-08-24.JSON and CSV
- Company record
- EDGAR filing index for CIK 1703057Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of ABCL is sold short?
30,934,912 shares were held short at the 2026-10-15 settlement, 5.6 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is ABCL's daily short volume?
On 2026-11-02, 518,678 of the 1,274,920 ABCL shares reported to FINRA were sold short, 40.7% of the day's reported volume. Short volume is a flow for one day, not a position.
Does ABCL have fails to deliver?
The SEC's latest file shows 1,463 ABCL shares failed to deliver at settlement 2026-10-06. Fails are reported per settlement date and published twice a month with a lag.
Are ABCL insiders buying or selling?
Insiders at ABCL reported 4 open-market buys worth $1.5M in the last 90 days and no open-market sells. Latest filing: Hayden Michael R (Director) on 2026-08-24.
Who owns 5% or more of ABCL?
4 holders report 5% or more of ABCL in their latest filing, all on Schedule 13G (passive). The largest reported stake is Felix J. Baker at 10.8% of the class (33,012,138 shares), filed 2026-05-07 for an event on 2026-04-30.
What did ABCL report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) AbCellera Biologics reported revenue of $4.0M, down 76.3% from the same quarter a year earlier, and net loss of $55.4M (-0.18 diluted EPS). In FY 2025 it generated -$131.3M of operating cash flow.
Which tracked 13F managers own ABCL?
5 of the 30 tracked 13F managers held ABCL shares at their latest filing, $106.6M in all. The largest: Two Sigma Investments (10.4M shares, $81.9M), Ken Griffin's Citadel Advisors (1.6M shares, $12.5M), Renaissance Technologies (991K shares, $7.8M), Izzy Englander's Millennium Management (519K shares, $4.1M), D. E. Shaw & Co. (45K shares, $357K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.